CBIO
Crescent Biopharma, Inc.
Biotechnology
Market Cap$506M
5Y Perf.-95.1%
Build Your Comparison
Side-by-side financial analysisCBIO
KYMR
Try popular comparisons:
Stock Comparison
CBIO vs KYMR
Revenue, margins, valuation, and 5-year total return — side by side.
KYMR
Kymera Therapeutics, Inc.
Biotechnology
Market Cap$6.77B
5Y Perf.+155.2%
CBIO vs KYMR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  CBIO |  KYMR |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $506M | $6.77B |
| Revenue (TTM) | $12M | $51M |
| Net Income (TTM) | $-162M | $-315M |
| Gross Margin | 100.0% | 33.2% |
| Operating Margin | -13.7% | -7.0% |
| Total Debt | $2M | $82M |
| Cash & Equiv. | $213M | $357M |
CBIO vs KYMR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CBIO
KYMR
| Stock | Aug 20 | Jun 26 | Return |
|---|---|---|---|
| Crescent Biopharma,… (CBIO) | 100 | 4.9 | -95.1% |
| Kymera Therapeutics… (KYMR) | 100 | 255.2 | +155.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CBIO vs KYMR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: KYMR leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. Crescent Biopharma, Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
🥇KYMR emerged as the overall leader. Track its performance:
CBIO
Crescent Biopharma, Inc.
The Income Pick
CBIO is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 0.82
- Lower volatility, beta 0.82, Low D/E 0.8%, current ratio 6.56x
- Beta 0.82, current ratio 6.56x
Best for: income & stability and sleep-well-at-night
KYMR
Kymera Therapeutics, Inc.
The Growth Play
KYMR carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth -16.7%, EPS growth -23.8%, 3Y rev CAGR -5.8%
- 149.4% 10Y total return vs CBIO's -97.7%
- -6.1% margin vs CBIO's -13.6%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  CBIO | 365.3% revenue growth vs KYMR's -16.7% |
| Quality / Margins |  KYMR | -6.1% margin vs CBIO's -13.6% |
| Stability / Safety | CBIO | Beta 0.82 vs KYMR's 0.90, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | KYMR | +71.4% vs CBIO's +10.5% |
| Efficiency (ROA) | KYMR | -22.3% ROA vs CBIO's -88.2% |
CBIO vs KYMR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
CBIO vs KYMR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLKYMRLAGGINGCBIO
CBIOCrescent Biopharma, I…
1leads
KYMRKymera Therapeutics, …
2leads
6 Total Categories
CATEGORYLEADERvs CBIOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
KYMR3/5
Valuation MetricsMultiples, price ratios, and targets
CBIO2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
KYMR5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
KYMR leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
KYMR is the larger business by revenue, generating $51M annually — 4.3x CBIO's $12M. KYMR is the more profitable business, keeping -6.1% of every revenue dollar as net income compared to CBIO's -13.6%.
| Metric | CBIOCrescent Biopharm… | KYMRKymera Therapeuti… |
|---|---|---|
| RevenueTrailing 12 months | $12M | $51M |
| EBITDAEarnings before interest/tax | -$163M | -$352M |
| Net IncomeAfter-tax profit | -$162M | -$315M |
| Free Cash FlowCash after capex | -$27M | -$244M |
| Gross MarginGross profit ÷ Revenue | +100.0% | +33.2% |
| Operating MarginEBIT ÷ Revenue | -13.7% | -7.0% |
| Net MarginNet income ÷ Revenue | -13.6% | -6.1% |
| FCF MarginFCF ÷ Revenue | -2.3% | -4.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +55.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +10.3% | +13.4% |
KYMR leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
CBIO leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | CBIOCrescent Biopharm… | KYMRKymera Therapeuti… |
|---|---|---|
| Market CapShares × price | $506M | $6.8B |
| Enterprise ValueMkt cap + debt − cash | $294M | $6.5B |
| Trailing P/EPrice ÷ TTM EPS | -1.43x | -22.48x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 46.63x | 172.78x |
| Price / BookPrice ÷ Book value/share | 0.94x | 4.43x |
| Price / FCFMarket cap ÷ FCF | — | — |
CBIO leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
Evenly matched — CBIO and KYMR each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
KYMR delivers a -25.0% return on equity — every $100 of shareholder capital generates $-25 in annual profit, vs $-101 for CBIO. CBIO carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to KYMR's 0.05x. On the Piotroski fundamental quality scale (0–9), CBIO scores 7/9 vs KYMR's 4/9, reflecting strong financial health.
| Metric | CBIOCrescent Biopharm… | KYMRKymera Therapeuti… |
|---|---|---|
| ROE (TTM)Return on equity | -100.9% | -25.0% |
| ROA (TTM)Return on assets | -88.2% | -22.3% |
| ROICReturn on invested capital | — | -24.9% |
| ROCEReturn on capital employed | -132.6% | -27.2% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 4 |
| Debt / EquityFinancial leverage | 0.01x | 0.05x |
| Net DebtTotal debt minus cash | -$212M | -$275M |
| Cash & Equiv.Liquid assets | $213M | $357M |
| Total DebtShort + long-term debt | $2M | $82M |
| Interest CoverageEBIT ÷ Interest expense | -148.19x | -2119.53x |
Evenly matched — CBIO and KYMR each lead in 4 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
KYMR leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KYMR five years ago would be worth $16,412 today (with dividends reinvested), compared to $667 for CBIO. Over the past 12 months, KYMR leads with a +71.4% total return vs CBIO's +10.5%. The 3-year compound annual growth rate (CAGR) favors KYMR at 48.9% vs CBIO's -53.6% — a key indicator of consistent wealth creation.
| Metric | CBIOCrescent Biopharm… | KYMRKymera Therapeuti… |
|---|---|---|
| YTD ReturnYear-to-date | +65.5% | +14.0% |
| 1-Year ReturnPast 12 months | +10.5% | +71.4% |
| 3-Year ReturnCumulative with dividends | -90.0% | +230.0% |
| 5-Year ReturnCumulative with dividends | -93.3% | +64.1% |
| 10-Year ReturnCumulative with dividends | -97.7% | +149.4% |
| CAGR (3Y)Annualised 3-year return | -53.6% | +48.9% |
KYMR leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — CBIO and KYMR each lead in 1 of 2 comparable metrics.
Risk & Volatility
CBIO is the less volatile stock with a 0.82 beta — it tends to amplify market swings less than KYMR's 0.90 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KYMR currently trades 80.5% from its 52-week high vs CBIO's 66.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CBIOCrescent Biopharm… | KYMRKymera Therapeuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.82x | 0.90x |
| 52-Week HighHighest price in past year | $27.41 | $103.00 |
| 52-Week LowLowest price in past year | $8.72 | $36.65 |
| % of 52W HighCurrent price vs 52-week peak | +66.9% | +80.5% |
| RSI (14)Momentum oscillator 0–100 | 43.6 | 47.7 |
| Avg Volume (50D)Average daily shares traded | 270K | 493K |
Evenly matched — CBIO and KYMR each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates CBIO as "Buy" and KYMR as "Buy". Consensus price targets imply 79.9% upside for CBIO (target: $33) vs 44.6% for KYMR (target: $120).
| Metric | CBIOCrescent Biopharm… | KYMRKymera Therapeuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $33.00 | $119.93 |
| # AnalystsCovering analysts | 13 | 26 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
KYMR leads in 2 of 6 categories (Income & Cash Flow, Total Returns). CBIO leads in 1 (Valuation Metrics). 2 tied.
Best OverallKymera Therapeutics, Inc. (KYMR)Leads 2 of 6 categories
Loading custom metrics...
CBIO vs KYMR: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is CBIO or KYMR a better buy right now?
Analysts rate Crescent Biopharma, Inc.
(CBIO) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CBIO or KYMR?
Over the past 5 years, Kymera Therapeutics, Inc.
(KYMR) delivered a total return of +64. 1%, compared to -93. 3% for Crescent Biopharma, Inc. (CBIO). Over 10 years, the gap is even starker: KYMR returned +149. 4% versus CBIO's -97. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CBIO or KYMR?
By beta (market sensitivity over 5 years), Crescent Biopharma, Inc.
(CBIO) is the lower-risk stock at 0. 82β versus Kymera Therapeutics, Inc. 's 0. 90β — meaning KYMR is approximately 10% more volatile than CBIO relative to the S&P 500. On balance sheet safety, Crescent Biopharma, Inc. (CBIO) carries a lower debt/equity ratio of 1% versus 5% for Kymera Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — CBIO or KYMR?
On earnings-per-share growth, the picture is similar: Kymera Therapeutics, Inc.
grew EPS -23. 8% year-over-year, compared to -815. 0% for Crescent Biopharma, Inc.. Over a 3-year CAGR, CBIO leads at 424. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CBIO or KYMR?
Kymera Therapeutics, Inc.
(KYMR) is the more profitable company, earning -794. 4% net margin versus -1419. 6% for Crescent Biopharma, Inc. — meaning it keeps -794. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KYMR leads at -891. 3% versus -1407. 5% for CBIO. At the gross margin level — before operating expenses — CBIO leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — CBIO or KYMR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is CBIO or KYMR better for a retirement portfolio?
For long-horizon retirement investors, Kymera Therapeutics, Inc.
(KYMR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 90), +149. 4% 10Y return). Both have compounded well over 10 years (KYMR: +149. 4%, CBIO: -97. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CBIO and KYMR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.